Table 1.
Clinical data and histological features of 56 DLBCL patients
| Age (years) | |
| Median (IQR) | 52.25 (16) |
| Range | (19–87) |
| >60 | 11 (19.64 %) |
| Gender | |
| Male/female | 32 (57.14 %)/24 (42.86 %) |
| Stage | |
| I | 1 (1.78 %) |
| II | 15 (26.78 %) |
| III | 21 (37.5 %) |
| IV | 19 (33.92 %) |
| ECOG | |
| 0 | 26 (46.43 %) |
| 1 | 21 (37.50 %) |
| 2 | 6 (10.71 %) |
| 3 | 3 (5.35 %) |
| B symptoms | 31 (55.35 %) |
| IPI | |
| Low | 23 (41.1 %) |
| Low/intermediate | 16 (28.6 %) |
| High/intermediate | 10 (17.9 %) |
| High | 7 (12.5 %) |
| Bulky disease (≥7 cm) | 29 (51.8%) |
| (≥10 cm) | 12 (21.4 %) |
| Extranodal localization | 19 (33.9 % |
| LDH (>460U/L) | 34 (60.7 %) |
| Median (IQR) | 570 (330) |
| Range | 214–2,598 |
| β-2-Microglobulin (mg/L) | |
| Median(IQR) | 4.3 (3.7) |
| Range | 1.18–13.9 |
| CRP (mg/L) | |
| Median(IQR) | 15.5 (35.7) |
| Range | 1.7–285 |
| Lymphocyte count (×109/L) | 1.8 (1.2) |
| Range | 0.3–11 |
| Therapy | |
| R-CHOP/R-EPOCH | 51 (91.07 %)/5 (8.93 %) |
| GBC/non-GBC subtype | 19 (51.4 %)/18 (48.6 %) |